BeStock  
Stocks › Biotechnology › DSGN

Design Therapeutics DSGN

US equityMarket cap rank #3474Biotechnology
$11.69 −$0.28 (-2.34%)
Pre-market · Oct 8, 8:20 am ET · After hours $11.69 0.00%
Open$11.82
Prev close$11.97
Day range$11.58 – $12.06
Volume344.5K
Market cap$731.58M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$22.18M-2.8% YoY
Net profit-$20.17M-5.7% YoY
Diluted EPS-$0.32+5.9% YoY
Free cash flow-$15.55M-7.0% YoY
Operating cash flow-$15.52M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-13.0MSep '24$-13.7MDec '24$-17.7MMar '25$-19.1MJun '25$-17.0MSep '25$-16.0MDec '25$-17.6MMar '26$-20.2MJun '26

Diluted EPS by quarter

-0.23Sep '24-0.24Dec '24-0.31Mar '25-0.34Jun '25-0.30Sep '25-0.27Dec '25-0.29Mar '26-0.32Jun '26

Free cash flow by quarter

$-9.5MSep '24$-9.9MDec '24$-16.9MMar '25$-14.5MJun '25$-11.2MSep '25$-12.0MDec '25$-16.4MMar '26$-15.5MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-34.1%
Return on assets-32.3%
Return on invested capital-37.8%
Current ratio18.86
Liabilities / assets6.2%
Cash & investments$207.40M
Total debt$2.03M
Net cash (debt)$205.37M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $22.18M $19.71M $79.47M $18.17M $19.31M
Selling and Admin Expenses $5.79M $5.33M $20.34M $4.74M $4.72M
-General & Admin Expense $5.79M $5.33M $20.34M $4.74M $4.72M
Research & Development $16.39M $14.38M $59.13M $13.43M $14.59M
Operating Profit -$22.18M -$19.71M -$79.47M -$18.17M -$19.31M
Net Non-Operating Interest Income (Expense) $2.01M $2.07M $9.68M $2.17M $2.31M
Non-Operating Interest Income $2.01M $2.07M $9.68M $2.17M $2.31M
Pretax Profit -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Net Profit -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Profit from Continuing Operations -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Net Income to Parent Company -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Net Income to Common Stockholders -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Basic EPS -$0.32 -$0.29 -$1.22 -$0.27 -$0.30
Diluted EPS -$0.32 -$0.29 -$1.22 -$0.27 -$0.30

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $215.13M $230.44M $226.20M $226.20M $211.77M
Total Current Assets $212.01M $227.05M $223.78M $223.78M $209.03M
Cash and Cash Equivalents & Short-Term Investments $207.40M $222.82M $219.85M $219.85M $205.97M
-Cash and Cash Equivalents $12.91M $12.77M $16.86M $16.86M $15.09M
-Short Term Investments $194.49M $210.05M $202.99M $202.99M $190.88M
Receivables $1.79M $1.82M $1.68M $1.68M $1.38M
-Accrued Interest Receivable $1.79M $1.82M $1.68M $1.68M $1.38M
Prepaid Assets $2.83M $2.40M $2.26M $2.26M $1.68M
Total Non-Current Assets $3.12M $3.39M $2.42M $2.42M $2.74M
Net PPE $3.12M $3.39M $2.42M $2.42M $2.74M
-Gross PPE $5.69M $5.81M $4.68M $4.68M $4.85M
-Accumulated Depreciation -$2.57M -$2.42M -$2.26M -$2.26M -$2.11M
Total Liabilities $13.27M $12.39M $13.70M $13.70M $12.05M
Total Current Liabilities $11.24M $10.19M $13.06M $13.06M $11.17M
Payables $3.14M $2.28M $2.31M $2.31M $1.91M
-Accounts Payable $3.14M $2.28M $2.31M $2.31M $1.91M
Current Accrued Expenses $4.68M $5.05M $5.22M $5.22M $4.93M
Short-Term Debt and Capital Lease Obligation $631,000.00 $536,000.00 $890,000.00 $890,000.00 $866,000.00
-Current Capital Lease Obligation $631,000.00 $536,000.00 $890,000.00 $890,000.00 $866,000.00
Total Non-Current Liabilities $2.03M $2.20M $645,000.00 $645,000.00 $877,000.00
Long Term Debt and Capital Lease Obligation $2.03M $2.20M $645,000.00 $645,000.00 $877,000.00
-Long Term Capital Lease Obligation $2.03M $2.20M $645,000.00 $645,000.00 $877,000.00
Total Equity $201.86M $218.05M $212.50M $212.50M $199.72M
Stockholders' Equity $201.86M $218.05M $212.50M $212.50M $199.72M
Capital Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
-Common Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
Additional Paid-In Capital $537.43M $532.96M $509.10M $509.10M $480.37M
Retained Earnings -$334.81M -$314.64M -$297.01M -$297.01M -$281.01M
Gains/Losses Not Affecting Retained Earnings -$771,000.00 -$268,000.00 $403,000.00 $403,000.00 $358,000.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$15.52M -$16.43M -$54.36M -$11.97M -$11.16M
Net cash flow from continuing operations -$15.52M -$16.43M -$54.36M -$11.97M -$11.16M
Net Income from Continuing Operations -$20.17M -$17.64M -$69.79M -$16.00M -$17.00M
Depreciation & Depletion & Amortization $151,000.00 $157,000.00 $622,000.00 $156,000.00 $155,000.00
Other Non-Cash Items $74,000.00 $69,000.00 $406,000.00 -$8,000.00 -$7,000.00
Change in Working Capital $564,000.00 -$2.80M $3.11M $960,000.00 $2.86M
-Change in Prepaid Assets -$391,000.00 -$287,000.00 -$1.38M -$880,000.00 $459,000.00
-Change in Payables and Accrued Expense $955,000.00 -$2.51M $4.49M $1.84M $2.41M
Net cash flow from investing $15.06M -$7.59M $22.91M -$11.58M $6.51M
Net Cash Flow from Continuing Investing Activities $15.06M -$7.59M $22.91M -$11.58M $6.51M
Net PPE Purchase and Sale -$21,000.00 $0.00 -$193,000.00 -$34,000.00 $0.00
Net Investment Purchase and Sale $15.08M -$7.59M $23.11M -$11.55M $6.51M
Financing Cash Flow $605,000.00 $19.93M $25.74M $25.32M $37,000.00
Net Cash Flow from Continuing Financing Activities $605,000.00 $19.93M $25.74M $25.32M $37,000.00
Net Common Stock Issuance $0.00 $19.91M $24.85M – –
Proceeds from Stock Option Exercised $605,000.00 $27,000.00 $891,000.00 $470,000.00 $37,000.00
Ending Cash Balance $12.91M $12.77M $16.86M $16.86M $15.09M
Net Change in Cash $137,000.00 -$4.09M -$5.71M $1.77M -$4.62M
Beginning Cash Balance $12.77M $16.86M $22.56M $15.09M $19.70M
Free Cash Flow -$15.55M -$16.43M -$54.55M -$12.00M -$11.16M

Discussion

No comments yet — be the first to weigh in on DSGN.

Leave a comment

Scroll to Top